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The serotonin-1A receptor (5-HT1A-R) is an abundant 5-HT receptor located in both 
pre-synaptic and post-synaptic membranes of neurons. Activation of this receptor has been 
involved in the mechanism of action of antidepressant, antipsychotic and anxiolytic drugs. 
Thus, studies of 5-HT1A-Rs might help to manage various psychiatric diseases. 
 
SUMOylation of 5-HT1A-Rs has recently been reported and evidence suggests that 
SUMOylation might play an important role in the regulation of 5-HT1A-Rs. Previous studies 
in our lab found that 5-HT1A-Rs can be modified by SUMO-1 in rat brain and 
neuroblastoma2a cells. The majority of SUMO-1-5-HT1A-Rs are co-localized with 
endoplasmic-reticulum and trans-Golgi-network markers. Treatment with the 5-HT1A-R 
agonist, 8-OH-DPAT, increases SUMO-1-5-HT1A-Rs in the detergent-resistant membrane 
(DRM). SUMO-1-5-HT1A-Rs minimally bind to 5-HT1A-R agonist. Investigating the 
mechanism involved in the SUMOylation of 5-HT1A-R will help to understand the 
regulation of 5-HT1A-R and may lead to the development of novel therapeutic approaches 
for psychiatric diseases. 
 
In this study, I focused on the SUMO machinery regulating deSUMOylation of 5-HT1A-Rs 
and the SUMOylation sites on 5-HT1A-Rs. I found that mouse Neuroblastoma 2a (N2a) cells 
can express exogenous 5-HT1A-Rs and verified expression of endogenous SUMOylation of 
5-HT1A-Rs. The SUMOylation of 5-HT1A-Rs was detected around 55KD in N2a cells 
which is consistent to our previous finding in rat brain. In addition, N2a cells can express 
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transfected sentrin-specific proteases (SENPs) proteins in the membrane fraction. 
Transfection of SENP1, 2 and 6 causes a significant difference among groups but there is no 
significant difference between each transfected SENPs group compared to the 
non-transfected control group.  
 
To identify the SUMOylation sites on 5-HT1A-Rs, six possible SUMOylation sites on 
5-HT1A-R: K302, K332, K324, K232 and K235 were mutated into nonSUMOylatable 
arginine residues. I transfected each 5-HT1A-R mutant into N2a cells and found that 
transfection of each 5-HT1A-R mutant does not reduce SUMOylation of 5-HT1A-Rs. 
However, SUMOylation of transfected rat 5-HT1A-Rs has a different molecular mass 
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Chapter I: Introduction 
 
 
1.1. Serotonin and Serotonin neurons 
Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter derived 
from tryptophan. It is found primarily in the gastrointestinal tract, blood platelets, and 
central nervous system. The gastrointestinal tract produces around 95% of serotonin 
[1-3]. It is also involved in healing wounds, stimulating nausea, and maintaining bone 
health. In the central nervous system, serotonin is associated with temperature 
regulation, circadian rhythmicity, vomiting, aggression, and energy balance [4]. 
Serotonin plays a role in psychiatric diseases such as depression, anxiety, and 
schizophrenia. Serotonin can be taken up by cells such as platelets and neurons 
through the serotonin transporter (SERT). Serotonin can also be transported via a 
vesicular monoamine transporter (VMAT) into vesicles [5]. After it is transported into 
vesicles, serotonin is released via exocytosis into the synaptic cleft and thereafter 
binds to pre and post-synaptic serotonin receptors. Serotonergic neurons develop from 
mesopontine and medullary primordia, which group into rostral and caudal clusters 
that are maintained into adulthood [6]. Serotonergic neurons originate in the dorsal 
and median raphe nucleus of the caudal midbrain. Neurons within the rostral raphe 
complex project to the forebrain, neurons within the caudal raphe complex primarily 
project to the brainstem nuclei and to the spinal cord [6]. In fact, every cell in the 




All serotonin receptors belong to the G-protein coupled receptor family, except the 
5-HT3 receptor which is a ligand-gated ionotropic receptor [8]. Serotonin receptors 
can be subdivided into 7 families based on the type of G proteins to which they are 
coupled. Serotonin 1 receptors (5-HT1-Rs) or serotonin 5 receptors (5-HT5-Rs) 
couple to Gαi/Gαo proteins; the serotonin 2 receptors (5-HT2-Rs) bind to Gαq/11 
proteins; the serotonin 4 receptors (5-HT4-Rs), serotonin 6 receptors (5-HT6-Rs) and 
serotonin 7 receptors (5-HT7-Rs) couple to Gαs proteins [9]. Different subtypes of 
serotonin receptors activate different signaling pathways based on the Gα protein to 
which it couples. For example, activation of Gαs coupled receptors leads to elevation 
of cyclic AMP(cAMP), which is a second messenger associated with other proteins 
such as ion channels and protein kinase A (PKA). In contrast, activation of the Gαi 
receptor leads to downregulation of cAMP [10]. The activation of Gαq/11 coupled 
receptors activates protein kinase C (PKC) and results in the formation of 
diacylglycerol (DAG) and inositol-phosphate (IP3), which leads to the elevation of 
intracellular calcium [11]. Other factors also contribute to the diversity of serotonin 
receptors. There are thirteen genes coding for GPCR serotonin receptors that couple 
to almost every G-protein in the cell membrane and probably act without coupling to 
them [12]. Also, this diversity is made more complex by posttranslational 
modifications [12]. 
1.2. 5-HT1A receptor 
5-HT1A-R is a subtype of serotonin receptor which binds to serotonin with a high 
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affinity. It has a molecular weight around 42kDa with 422 amino acids. 5-HT1A-Rs 
exist in many regions of the brain, but different regions express different densities of 
5-HT1A-Rs. A recent study on the distribution of human 5-HT1A-R using 
autoradiography and positron emission tomography (PET) demonstrated higher levels 
of 5-HT1A-R in the infralimbic cortex, hippocampus (specifically within CA1), 
cingulate cortex, neocortex and raphe nuclei. Lower levels of 5-HT1A-R were  
reported in the basal ganglia and cerebellum [13]. From previous studies, the major 
effect of 5-HT1A-R stimulation is the activation of hyperpolarizing K+ channels, 
resulting in the inhibition of neuronal firing. 5-HT1A-Rs are also involved in different 
signaling pathways such as regulation of phospholipase C activity, inhibition of 
cAMP production and reduction of calcium currents [14]. 5-HT1A-Rs are located at 
pre- and post-synaptically. Pre-synaptic 5-HT1A-R are  present in the serotonergic 
neurons with cell bodies located in raphe nuclei [15]. Serotonin release is thought to 
activate pre-synaptic auto-receptors, thus completing an autoinhibitory feedback loop 
[16]. Post-synaptic 5-HT1A-Rs are abundantly expressed in the hippocampus, septum, 
amygdala, and prefrontal cortex [17]. Activation of post-synaptic 5-HT1A-Rs 
mediates serotonin actions on fear, anxiety, stress and cognitive function [17]. 
5-HT1A-R is involved in many psychiatric disorders such as depression, anxiety, and 
schizophrenia. The role of 5-HT1A-Rs in anxiety disorders is well studied. A study in 
5-HT1A-R knockout mice showed an increasing anxiety behaviors [1]. The role of 
5-HT1A-Rs in schizophrenia remains unclear. However, a study in 5-HT1A-R 
knockout and knockdown mice showed that 5-HT1A-Rs are necessary for the atypical 
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antipsychotic drug induced elevation in cortical dopamine transmission [2]. Studies 
have shown an elevation in cortical 5-HT1A-R density in schizophrenia patients, 
which also suggests the role of 5-HT1A-Rs in schizophrenia [3]. The role of 
5-HT1A-Rs in depression has been extensively studied. Antidepressants such as 
tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) 
both alter 5-HT1A-R signaling by direct or indirect mechanisms. Increased DNA 
methylation of the 5-HT1A-R promoters in brains of suicide victims has also been 
reported [18]. Further, a study in serotonin transporter knockout mice suggested that 
early life blockade of 5-HT1A-Rs normalizes depression-like behaviors [19]. Thus, 
5-HT1A-Rs appear to play an important role in mental health and may be a useful 
target in the management of various psychiatric diseases.  
 
5-HT1A-Rs can be modified by phosphorylation, glycosylation, palmitoylation and 
SUMOylation. Glycosylation is a process in which a carbohydrate is attached to a 
hydroxyl or other glycosyl acceptor molecule. Glycosylation of 5-HT1A-Rs takes 
place in the trans-Golgi network and is involved in transporting the receptor from the 
cytosol to the membrane [20].  
Palmitoylation is a covalent attachment of the fatty acid and the palmitic acid to 
cysteine, serine and threonine residues of a protein. Palmitoylation of 5-HT1A-R 
occurs early after synthesis of the 5-HT1A-R [21]. Replacement of cysteine residues 
(417 or 420) prevented palmitoylation, reduced binding of 5-HT1A-R with Gi and 
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impaired inhibition of adenylyl cyclase activity [21]. In fact, when both palmitoylated 
cysteines were mutated, the association of 5-HT1A-R with Gi was completely 
abolished [21]. Moreover, non-palmitoylatable mutants were not able to inhibit 
forskolin-stimulated cAMP formation, suggesting that palmitoylation of the 
5-HT1A-R is important for the Gi signaling [21].  
Phosphorylation of 5-HT1A-Rs is thought to be involved in desensitization of 
5-HT1A-Rs [22]. Studies have shown that stimulation of protein-kinase C (PKC) by 
application of phorbol esters induces a rapid phosphorylation of the 5-HT1A-Rs [22]. 
PKC phosphorylation of the 5-HTlA-Rs leads to a decreased efficiency of coupling to 
G proteins [22]. Desensitization could be reversed by mutation of three putative PKC 
sites in the 5-HT1A-Rs, demonstrating a functional link between phosphorylation and 
desensitization of 5-HT1A-Rs [23]. 
Previous studies in our laboratory reported that 5-HT1A-Rs can be SUMOylated by 
SUMO1 protein [24]. The SUMO-1-5-HT1A-R is ~55 kDa, is located in the 
membrane fraction, but not the cytosol, and is distributed in all of the brain regions 
expressing 5-HT1A-Rs examined [24]. Acute stimulation of 5-HT1A-Rs significantly 
increased SUMO-1-5-HT1A-R in rat hypothalamus [24]. Pretreatment with estradiol 
for 2 days, which causes a partial desensitization of 5-HT1A-R signaling, potentiated 
agonist-induced increases in SUMO-1-5-HT1A-Rs in the hypothalamus of rats [24]. 
Using discontinuous gradient centrifugation followed by digitonin treatment, we 
found that the majority of SUMO-1-5-HT1A-Rs is co-localized with 
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endoplasmic-reticulum and trans-Golgi-network markers [24]. Although a small 
proportion of SUMO-1-5-HT1A-Rs are located in the detergent resistant 
microdomain (DRM) that contain active G-protein coupled receptors, their 
distribution was different from that of the Gαz protein that couples to the receptors 
[24]. These data suggest that the SUMO-1-5-HT1A-Rs are an inactive form of 
5-HT1A-Rs, a finding further supported by results showing minimal 5-HT1A-R 
agonist binding to SUMO-1-5-HT1A-Rs [24]. Furthermore, SUMO1- 5-HT1A-Rs in 
the DRM were increased by treatment with a 5-HT1A-R agonist, 8-OH-DPAT [24]. 
Together, these data suggest that SUMOylation of 5-HT1A-Rs may be related to 
5-HT1A-R trafficking and internalization, which may contribute to 5-HT1A-R 
desensitization [24]. Therefore, understanding the mechanism of SUMOylation of 
5-HT1A-Rs will help us understand the regulatory mechanisms of these receptors in 
disease and provide potential targets for further diagnostic and therapeutic 
consideration. 
1.3. SUMOylation 
SUMOylation is the covalent binding of a SUMO group to a lysine residue of its 
substrates. It reversibly modulates the activity, stability, and the intracellular 
localization of proteins. Unlike chemical modifications such as phosphorylation, 
glycosylation, and methylation, SUMOylation is a small peptide called small 
ubiquitin-like modifier (SUMO). In fact, a large family of ubiquitin-like modifiers 
have been identified, SUMO, Nedd8, ISG15, FAT10, FUB1, UFM1, URM1, Atg12 
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and Atg8 [27].  
The process of SUMOylation is carried out by an enzymatic cascade of 4 enzymes. 
The first step in SUMOylation is the maturation of pre-SUMO proteins by SUMO 
proteases. SUMO proteases can cleave the C-terminus of the SUMO precursor protein 
resulting in a C-terminal glycine residue to allow the formation of an isopeptide bond 
between this glycine residue of SUMO and the lysine residue of the substrate. Then 
SUMO protein needs to be activated by E1 enzymes, followed by conjugation to the 
E2 enzyme, Ubc9. E3 ligases may help to transfer SUMO protein to substrates. The 
SUMOylation process is reversed by SUMO proteases. SUMO proteases catalyze the 
removal of SUMO from SUMO-conjugated substrate proteins, and this process is 
called deSUMOylation. Although SUMOylation and ubiquitylation share many 
similarities, the number of related enzymes is different. There are several E2 and more 
than 600 E3 enzymes regulating ubiquitylation while only one E1 enzyme 
(SAE1/SAE2), one E2 enzyme (Ubc9) and only a few E3 enzymes that regulate 
SUMOylation have been discovered so far [25].  
Previous studies revealed that most of the lysine residues that are SUMOylated lie 
within a specific consensus motif: ΨKXE (ψ, a hydrophobic amino acid; X, any 
amino acid residue) [28]. However, recent studies suggest that around 40% of 
SUMOylation site do not lie within this motif [29], and analysis of SUMOylation and 
SUMO interaction is still challenging.  
Studies also suggest that SUMOylation contributes to disease onset and progression. 
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SUMO modification has been associated with cancer, pathogenic infections and 
neurodegeneration [26-28]. Notably, it has been reported that SUMOylation supports 
tumor growth [29]. Also, studies have suggested the that SUMOylation pathway plays 
an important role in regulating cardiovascular function [25]. Overexpression of 
Sentrin-specific protease 2 (SENP2) and expression of an SUMOylation-deficient 
mutant of the cardiac-specific homeobox protein (Nkx2.5) leads to congenital heart 
defects and cardiac dysfunctions in mice [30]. Many of the key proteins in various 
neurodegenerative diseases are SUMO targets such as huntingtin, tau, DJ1, 
α-synuclein and superoxide dismutase 1 [25]. There are some studies which indicate 
that SUMOylation helps to prevent neurons from damage triggered by transient 
ischemia [31]. Therefore, investigating the mechanism of SUMOylation will help us 
understand the mechanisms of disease and inform new therapeutic approaches for 
these diseases.   
1.3.1. Small Ubiquitin-like Modifier (SUMO) proteins  
In mammalian cells, there are 4 SUMO paralogues: SUMO-1, SUMO-2, SUMO-3, 
and SUMO-4. SUMO-1, SUMO-2, and SUMO-3 are detected in all tissues, whereas 
the existence of SUMO4 has only been demonstrated in the kidneys, dendritic cells, 
and macrophages [32]. SUMO-1 is 45% identical to SUMO-2 and SUMO-3. 
SUMO-2 and SUMO-3 share 95% identity and are often referred to as SUMO-2/3. 
Some SUMO substrates only associate with SUMO-1 protein, some only associate 
with SUMO-2/3, while others can associate with all SUMO proteins. For example, 
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RanGap1 is the major substrate for SUMO-1 but can still be modified by SUMO-2/3 
[33]. Cells contain a larger pool of SUMO-2/3 compared to SUMO-1, which might be 
because SUMO-2/3 is responsible for polySUMO chain formation. A conserved 
lysine sequence ΨKXE (ψ, a hydrophobic amino acid; X, any amino acid residue) in 
the N-terminal of SUMO-2/3 can be SUMOylated, and can lead to the formation of 
the polySUMO chains. SUMO-1 does not have this conserved lysine site and does not 
play a role in the formation of the polySUMO chain [34]. However, SUMO-1 might 
terminate polySUMO chains as a cap at the end of the polySUMO chain [34]. 
Furthermore, studies reveal that conjugation to SUMO-2/3 appears under stress 
conditions, but SUMO-1 conjugation does not [33]. Although the biological relevance 
of SUMO-4 remains unclear, SUMO-4 can be matured by the stress-induced 
hydrolase and is able to conjugate to its substrates when cells are under stress 
conditions [35].    
1.3.2. SUMO-activating enzyme (E1)  
There are two E1 enzymes in mammals, Sae1 and Sae2. The E1 enzyme catalyzes the 
reaction of activating SUMO protein and transferring it to SUMO conjugation 
enzyme (Ubc9). The reaction is a 3 step reaction: In the first step, the carboxyl group 
of SUMO C-terminal attacks ATP and forms an SUMO-adenylate intermediate with 
the release of pyrophosphate [36]. In the second step, the SUMO C-terminal is 
transferred to the catalytic cysteine of Sae1, forming a high-energy thioester bond 
between Sae1 and the C-terminal glycine of SUMO and releasing AMP [36]. Finally, 
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the SUMO is transferred to SUMO-conjugating enzyme Ubc9 and forms another 
thioester bond [36]. 
1.3.3. SUMO-conjugating enzyme (Ubc9) 
Unlike the ubiquitin system, Ubc9 is the only SUMO conjugating enzyme in 
eukaryotic cells [37]. Human Ubc9 is a 17 kDa protein which is 100% identical to 
mouse [38]. In mammalian cells, Ubc9 is expressed in the nucleus, nuclear pore 
complex, nuclear envelope, cytoplasm and cell membrane [38]. It has a conserved 
cysteine residue in its active site and forms a thioester bond with SUMO [39]. It 
recognizes a specific motif of amino acid sequence in its substrates. The motif is 
described as ΨKxD/E where Ψ indicates a hydrophobic residue, followed by a lysine 
residue, a spacer, and an acidic residue. An isopeptide linkage between the C-terminus 
of SUMO and the target protein is formed, followed by the nucleophilic attack of the 
ε-amino group of a substrate lysine residue [38]. Studies have shown that Ubc9 can be 
SUMOylated at lysine14 and the SUMOylation of Ubc9 results in an enhanced 
interaction between SUMO interaction motif (SIM) of transcriptional factor Sp100 
and SUMO protein [40].  
1.3.4. SUMO ligases (E3) 
SUMO ligases facilitate SUMO transfer from Ubc9 to its substrate. Some SUMO 
ligases have been described and can be divided into several classes such as: 
Siz/PIAS-family proteins, RanBP2, and other SUMO ligases. SUMO ligases might 
serve to (i) enhance the affinity of Ubc9 for a specific target, (ii) stabilize the Ubc9–
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target intermediate, (iii) help to orientate the acceptor lysine, or (iv) contribute to 
conjugation.  
1.3.4.1. Siz/PIAS-family proteins 
The Siz/PIAS-family of E3 ligases contain a RING finger-like domain, which is also 
called SP-RING motif [41]. The Siz/PIAS family includes PIAS1, PIAS3, PIASxα, 
PIASxβ, and PIASy in mammals. The RING finger-like domain is required for ligase 
activity but does not seem to contribute the catalytic residue to SUMO conjugation 
[39]. Siz/PIAS-family E3 ligases bind directly to Ubc9 and express substrate 
specificity. The five vertebrate PIAS proteins are involved in many processes, 
including gene expression, signal transduction and genome maintenance[42].  
1.3.4.2. RanBP2 
Studies have shown that RanBP2 expresses SUMO ligase activity in vitro [43]. 
RanBP2 is a nuclear pore complex protein that is located at the cytoplasmic pore. It 
contains an internal repeat domain (IR) which is two continuously repeated sequences 
of about 50 amino acids [44]. IR domain is required for SUMO ligase activity. 
RanBP2 facilitates SUMOylation in a substrate-independent manner. It promotes 
SUMOylation by folding around and aligning the Ubc9-SUMO intermediates in an 
optimal conformation that allows the interaction with lysine site of the substrate [45]. 
1.3.4.3. Other SUMO ligases 
Other proteins that have been reported as SUMO ligases include histone deacetylase 4 
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(HDAC4), Pc2, Topors and KRAB-associated protein (KPA1) [43]. HDAC4 is 
involved in the SUMOylation of myocyte-specific enhancer factor 2 (MEF 2) [46]. It 
binds to Ubc9 and facilitates the SUMOylation of MEF 2 [46]. The krab-associated 
protein contains a PHD-finger domain that promotes SUMOylation of an adjacent 
KAP1 bromodomain [47]. The PHD-finger and bromodomain associate together and 
bind to Ubc9 thus facilitating SUMOylation [47]. 
1.3.5. SUMO de-conjugating enzymes 
SUMO de-conjugating enzymes serve two major effects. First, the enzyme can cleave 
the C-terminus of the SUMO precursor protein resulting in a C-terminal glycine 
residue to allow the formation of an isopeptide bond between this glycine residue of 
SUMO and the lysine residue of the substrate. This reaction is referred to as the 
hydrolase activity of SUMO protease. Second, the enzyme can remove SUMO from 
its substrate by cleavage of an epsilon-linked peptide bond between the C-terminal 
glycine of the mature SUMO and the lysine epsilon-amino group of the target protein. 
This reaction is referred to as the isopeptidase activity of SUMO protease. SUMO 
de-conjugating enzymes were first described in yeast as UBL-specific proteases (UlPs) 
and include UlP1P, UlP2P. Later, six types of sentrin specific proteases (SENPs) were 
identified in humans followed by the discovery of 2 types of deSUMOylating 
isopeptidases (DESI1 and DESI2) and ubiquitin-specific proteases like-1 (USPL1) 
[48]. A list of various SUMO de-conjugating enzymes and their characteristics are 





















UIp1 Nuclear pole Smt3 Yes Yes No 
UIp2 Nucleoplasm Smt3 No Yes Yes 




Yes Yes Yes 





Yes Yes No 
SENP3 Nucleolus, 
Nucleoplasm 
SUMO-2/3 Unclear Yes No 
SENP5 Nucleolus, 
Mitochondria 
SUMO-2/3 Yes Yes No 
SENP6 Nucleoplasm SUMO-2/3 Yes Yes Yes 





Unclear Unclear Yes 
DESI-2 Cytoplasm Unclear No Yes Unclear 
USPL1 Cajal bodies SUMO-2/3 Yes Yes Yes 
 
1.3.5.1. Ubiquitin-like proteases (UlPs) 
The family of UlPs contains two enzymes: UlP1P and UlP2P. UlPs/SENPs share a 
conserved catalytic domain at C-terminal which is around 200 amino acids in length 
[43]. UlP1P is localized in the nuclear pole and is involved in the maturation of Smt3p 
[48]. UlP2P is localized in the nucleoplasm and plays a role in regulating the 
formation of poly-Smt3p chains [53].  
1.3.5.2. Sentrin specific proteases (SENPs) 
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In mammals, there are 7 SENPs (SENP1, SENP2, SENP3, SENP5, SENP6, SENP7 
and SENP8). Most of the SENPs are involved in the regulation of SUMOylation 
except SENP8. It is important to note that SENP8 is specific for Neddylation [54]. 
SENPs belong to the CE clan of cysteine proteases and share a common fold of their 
catalytic domain that encompasses the catalytic triad residues His478, Asp495, and 
Cys548 [49]. The domain architecture of each SENPs is shown in Figure 1. SENPs 
can be divided into 3 families. SENP1 and SENP2 belong to the first family because 
of the broad specificity for all SUMO isoforms [55]. The second family includes 
SENP3 and SENP5 for their preference on SUMO2/3 and localization in the 
nucleolus [55]. SENP6 and SENP7 also have a preference on SUMO2/3, but they 
have an additional loop inserted in the catalytic domain which makes them belong to 
the third family [55]. Different SENPs have distinct subcellular localizations. Studies 
have shown that their localizations are determined by their nonconserved N-terminal 
regions [56]. All SENPs can be activated by their substrate SUMO even though the 
mechanism remains unclear [49]. SENPs also exhibit selectivity toward SUMO 
substrates. Some studies indicate that substrate specificity of SENPs is an intrinsic 
characteristic while others suggest the importance of distinct localization of different 
SENPs [57]. Studies also suggest that the C-terminal end of each SUMO isoform 
might contribute to the preference of SENPs [58]. SENPs have been shown to play a 




Figure 1. The conserved catalytic domain is represented in black. White bars 
represent the N-terminal region which might be involve in the localization of SENPs. 
SENP6 and SENP7 have insertions in the catalytic domain. SENP8 shares the same 
catalytic domain with other SENPs but is not involved in the SUMOylation process 
[49].                  
1.3.5.2.1. SENP1 
Homo Sapien SENP1 is composed of 643 amino acids with a weight of 73 KD. The 
catalytic domain of SENP1 is formed by Cys602, His533 and Asp550 [59]. SENP1 
exists at the nuclear envelope and can efficiently remove all three SUMO isoforms 
from their targets [60]. Studies have suggested that SENP1 is involved in the 
formation of polySUMO chains by removing the SUMO-1 protein from the end of the 
polySUMO chain [61]. Moreover, it processes the SUMO-1, -2 and -3 precursors to 
remove a C-terminal pro-peptide to expose the C-terminal diglycine. Some studies 
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show that SENP1 knockdown mice exhibit an increased level of SUMO-1 
conjugation and accumulation of free SUMO-1, suggesting that SENP1 might have a 
preference to SUMO-1 [57]. Furthermore, studies have shown that SENP1 may itself 
be a target for SUMO-1 modification at a nonconsensus site [57]. Expression and 
localization of SUMO-1-conjugated target proteins play a pivotal role in the 
localization of SENP1 [57]. 
1.3.5.2.2. SENP2 
Homo Sapien SENP2 is a 589 amino acids protein [58]. It is located at the nuclear 
pole, nuclear foci, and cytoplasm. It can be subdivided into 2 subdomains. An 
N-terminal domain with α helices that contain the protease nucleophile, and a 
C-terminal with a five-stranded β sheet and 2 α helices [58]. The SENP2 active site is 
formed by a catalytic triad of amino acid residue including Cys548, His478, and 
Asp495, just like other cysteine protease active sites [58]. SENP2 regulates the 
maturation of pre-SUMO and has a preference for pre-SUMO-2 compared to 
pre-SUMO-1 and pre-SUMO-3 [58]. It recognizes and cleaves all SUMO isoforms 
but is not involved in the editing of the poly-SUMO chain. 
1.3.5.2.3. SENP3 and SENP5 
Homo Sapien SENP3 is a 574 amino acids protein and Homo Sapien SENP5 has 755 
amino acid residues. They are both found in the nucleolus while SENP3 can also be 
found in nucleoplasm and SENP5 also exists in the mitochondria. SENP3 has 
substrate specificity similar to that of SENP5; both of them exhibit a substrate 
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preference on SUMO2/3. The effect of SENP3 on SUMO maturation remains unclear, 
however, SENP5 exhibits hydrolase activity. The active site of SENP3 is formed by a 
catalytic triad of 3 amino acid residues including Cys532, His465, and Asp482. The 
SENP5 active site consists of Cys713, His646, and Asp663. Studies suggest that 
SENP3 plays an important role in regulating ribosome biogenesis by association with 
nucleophosmin1 [62, 63]. SENP5 might play a role in mitosis and cytokinesis [64]. 
Knockdown of SENP5 inhibits cell proliferation and alters the morphology of the 
nucleus [55]. SENP5 is also found in mitochondria and overexpression of SENP5 
deconjugates SUMO-1 from a number of mitochondrial substrates, and rescues 
SUMO-1 induced mitochondrial fragmentation. Also, knock down of SENP5 results 
in abnormal mitochondrial development [55]. 
1.3.5.2.4. SENP6 and SENP7 
Homo Sapien SENP6 consists of 1112 amino acids and Homo Sapien SENP7 has a 
984 amino acid residues protein. Both SENP6 and SENP7 have a preference for 
SUMO2/3 but do not regulate the maturation of pre-SUMO. SENP6 was initially 
thought to localize to the cytoplasm. However, further studies suggest that SENP6 as 
well as SENP7 localize in the nucleoplasm [55]. Both are involved in the editing of 
polySUMO chains [65]. Active sites of SENP6 include amino acid residues 637–1112 
[65]. The SENP7 catalytic domain includes amino acids 662–984[65]. Although the 
structure of SENP6 remains unclear, SENP6 and SENP7 share similar characteristics 
and have conserved sequence insertions in distinct positions within their catalytic 
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domains [65]. Structural studies of SENP7 revealed some unique features compared 
to other members from SENP/ULP family: 1. The lack of N-terminal α helix which 
exists in structures of SENP1, SENP2 and ULP1 [65]; 2. Four insertion loops; and 3. 
Alteration of some secondary structure elements in SENP7 compare to SENP1 or 
SENP2 [65]. Interestingly, recent studies note that the unexpected specificity of 
SENP6 and SENP7 distinguishes them from other members of SENPs family, 
suggesting that they might have substrates other than SUMO conjugates [66]. 
1.3.5.3. DeSUMOylating isopeptidases (DESI) 
DeSUMOylating isopeptidases are a set of newly discovered SUMO proteases 
belonging to a putative isopeptidase superfamily. Two types of deSUMOylating 
isopeptidases have been reported so far, including DESI-1 and DESI-2. DESI-1 and 
DESI-2 belong to a group of proteins called PPPDE (Permuted Papain fold Peptidases 
of Ds-RNA viruses and Eukaryotes) and contain around 140 amino acids [52]. The 
active sites of DESI-1 and DESI-2 are formed by the catalytic domain containing two 
conserved cysteine and histidine residues [67]. DESI-1 deconjugates both SUMO-1 
and SUMO2/3 while DESI-2 remains unclear [67]. In contrast to Ulp/SENP family 
members, the DESI-1 and DESI-2 enzymes have isopeptidase activity on a selected 
substrate but do not seem to process the maturation of pre-SUMO [52]. Although 
there are very limited studies about the substrate of DESIs, it is suggested that DESIs 
have different substrate specificity compared to SENPs [67].  
1.3.5.4. Ubiquitin-specific proteases like-1 (USPL1) 
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Ubiquitin-specific protease like-1 is a recently discovered SUMO protease. It belongs 
to cysteine protease USP family and has a molecular weight at 120 KD [68]. A 
structural study shows that a catalytic triad residues of Cys236, His 456, Asp472 
forms the active site of USPL1. Studies suggest that USPL1 can process pre-SUMO-1 
and pre-SUMO2 and has a preference for SUMO2/3 [68]. It also influences the 
editing of poly-SUMO chains, especially SUMO-3 chains [68]. USPL1 is found in the 
Cajal bodies colocalized with coilin [68]. Interestingly, global SUMOylation is not 
affected by the depletion of USPL 1, however, the distribution of coilin and cell 
proliferation was affected [68]. The mechanism remains unclear, but the catalytic 
domain of USPL 1 is not involved [68]. 
1.3.6. SUMO-interacting motif 
Substrates containing a specific motif can bind with SUMO non-covalently [69]. This 
specific motif is called SUMO-interacting motif (SIM). It was first observed in the 
SUMOylation of P73 [69]. Scientists found that certain proteins containing a 
Ser-X-Ser sequence flanked by a hydrophobic core on one side and acidic amino 
acids on the other can bind with SUMOylated P73 [69]. Further studies suggest that 
the hydrophobic core, with the consensus Val/ Ile-X-Val/Ile-Val/Ile (V/I-X-V/I-V/I) 
facilitates the interaction between SUMO and SIM-containing peptides [70]. Recent 
studies suggest that the hydrophobic core is an essential component of the SIM and it 
is usually juxtaposed to a negatively charged cluster of amino acids [71]. In some 
cases, SIM-containing proteins do not have this negatively charged amino acid 
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juxtaposed to the hydrophobic core. Phosphorylated serine and threonine residues all 
found adjacent to the hydrophobic SIM domains, which is a good way to introduce a 
negatively charged cluster into the SIM domains [72]. Interestingly, some studies even 
indicate that SUMO-2 prefers to conjugate with SIMs that lacks negatively charged 
amino acids, suggesting that the negatively charged cluster might affect the affinity, 
orientation and paralogue specificity of SUMO conjugation [72].  
The identification of SUMOylation sites in proteins and enzymes involved in 
SUMOylation is fundamental for improving the understanding of SUMOylation 
recognition, understanding the biological functions and regulatory mechanisms of 
SUMOs, and provides potential targets for further diagnostic and therapeutic 
considerations [73]. To study the mechanism of SUMOylation of 5-HT1A-Rs, we 
need to know what enzymes regulate the SUMOylation of 5-HT1A-Rs and the SUMO 
consensus sites on 5-HT1A-Rs. A previous study on the PIAS proteins in 
neuroblastoma 2a (N2a) cells demonstrated that PiasXα facilitates the SUMOylation 
of 5-HT1A-Rs in N2a cells. SUMO proteases involved in the SUMOylation of 
5-HT1A-Rs remains unclear. In this study, I focused on the deSUMOylation of 
5-HT1A-Rs and examined possible SUMOylation sites on 5-HT1A-Rs.  The specific 
aims of my thesis are as follows: 
Aim1: To determine which SENPs regulate the deSUMOylation of 5-HT1A-Rs. 
Aim2: To determine the SUMOylation sites on 5-HT1A-Rs. 
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Chapter II: Materials and Methods 
2.1. Plasmid constructs 
The plasmid constructs used in this project are listed in Table 1. 
QIAGEN®Plasmid Midi Kit (25) (Cat#12143, QIAGEN, USA) was used to 
isolate and purify plasmids. RGS-Senp3 and RGS-Senp5 were cut at BamH1/ 
Xho1 sites. Human Senp3 and Senp5 coding sequences were isolated and 
inserted in-frame into the pCMV-3Tag 2B vector at BamH1/ Xho1 sites. 
            Table 2. Summary of the plasmid constructs used 
Plasmid constructs Vector Tag Source 












































pcDNA4 HisMax C His,  
Xpress 
 
Flag-SENP1 pFLAG-CMV(4700bp) Flag 
Plasmid# 17357, 
Addgene 
Flag-SENP2 pFLAG-CMV(4700bp) Flag 
Plasmid# 18047, 
Addgene 
Myc-SENP3 pCMV3Tag-2B(4200bp) 3×Myc  
 
Myc-SENP5 pCMV3Tag-2B(4200bp) 3×Myc  
Flag-SENP6 pFLAG-CMV(4700bp) Flag 
Plasmid# 18065, 
Addgene 
RGS-SENP3 pcDNA3-RGS(5400bp) RGS 
Plasmid# 18048, 
Addgene 




2.2. Cell culture and harvesting 
Mouse Neuroblastoma 2a cells (N2a cells) were cultured in 50% Dulbecco's 
Modified Eagle Medium (1X DMEM, high glucose, pyruvate, Cat# 11995-073, 
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Thermo Fisher, USA) and 50% Opti-MEM (Cat# 31985088, Thermo Fisher, 
USA) supplemented with 10% Fetal Bovine Serum (FBS) (Cat# S11150, 
Atlanta Biologicals, USA) and 1% Penicillin-Streptomycin solution (Cat# 
P0781-100ML, Sigma, USA). N2a cells were transfected with mammalian 
expression plasmids using Lipofectamine 3000 (Cat# L3000015, Thermo 
Fisher, USA). The medium was changed 6 hours and 24 hours after 
transfection. 48 hours after transfection, cells were washed with 
phosphate-buffered saline and hypotonic buffer (0.25M sucrose 50 mM Tris, 
pH 7.5, 5mM EDTA, 100 mM NaCl). The cells were harvested in hypotonic 
buffer (20mM NEM, 1/100 dilution of phosphatase inhibitors and protease 
inhibitors were added before use), sonicated three times for 10s in ice with 
~30s interval to cool down the solution. After sonication, cells were 
centrifuged at 25000 x g 4oC for 1 hour. The supernatant was collected as the 
cytosol fraction. The pellet was suspended in solubilization buffer (20 mM 
Tris, pH 8, 1 mM EDTA, 100 mM NaCl. 1% sodium cholate hydrate, 20mM 
NEM, 1/100 dilution of phosphatase inhibitors and protease inhibitors) and 
sonicated 3 times for 10s each in ice with ~30s interval. After sonication, the 
vials were shaken horizontally at high speed, at 4oC for 1 hour, and samples 
were then centrifuged at 25000 x g, at 4 oC for 1 hour. The supernatant was 
collected as the solubilized membrane fraction. Protein samples were stored at 
-80 oC. Protein concentration was measured using the BCA protein assay (Cat# 
23228, Cat# 1859078, BCA Protein Assay, Thermo Fisher, USA). 
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2.3. Immunoprecipitation assay 
Protein from the N2a cell membrane fraction was used for the 
immunoprecipitation assays and incubated with mouse anti-SUMO-1 antibody, 
1:40 (Cat# sc-5308, Santa Cruz, USA), rabbit anti-SUMO-1 antibody, 1:125 
(donated by Dr. Yoshi Azuma), rabbit IgG control, 1:40 (Cat# 170-6515, 
Bio-Rad, USA) or mouse IgG control, 1:80 (Cat# sc-2025, Santa Cruz, USA) 
overnight at 4 oC. After incubation, 50ul of recombinant Protein G agarose 
(Cat# 15920-010, Invitrogen, USA) or Protein A affinity resins (Cat# 
10-2003-01, Repligen, USA) were used for precipitation. The beads were 
washed 3 times with IP buffer (50 mM Tris, pH 7.4, 10 mM EGTA, 100 mM 
NaCl, 0.5% Triton X-100, containing 20 mM NEM, 1X protease inhibitor 
cocktail, 1X phosphatase inhibitor cocktail I and II,) and incubated with 
protein samples and antibody at 4oC overnight. The beads were centrifuged at 
1000 x g at 4 oC for 3min. The pellets were collected, and the bound proteins 
were eluted with 50ul 2×SDS sample buffer (10g SDS in 100ml ddH2O with 
β-mercaptoethanol) and used for immunoblot assays. 
2.4. Immunoblot assay 
Protein samples were separated using SDS-PAGE as previously described [74] 
and then transferred to PVDF membranes. After transferring, the PVDF 
membranes were incubated in 5% non-fat milk in Tris-buffered saline, pH 7.6, 
with 0.1% Tween-20. The membranes were incubated overnight with primary 
antibodies as described and listed in Table 2. The proteins were detected with 
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an ECL detection kit (Cat# WBLUR0500, Millipore, USA, Cat# 10026384, 
Cat# 10026385, BioRad, USA). 
 
Table 2. Antibodies used for immunoprecipitation and immunoblots 
Antibodies Dilution Source 
Rabbit anti-5-HT1A-Rs 
1:1000 
Cat# PA5-28090, Thermo 
Fisher, USA 
Rat-anti-Flag 1:2000 Cat# 200474-21, Agilent, USA 
Mouse-anti-Na+,K+, 
ATPase 
1:1000 Cat# 05-369, Millipore, USA 
Mouse-anti-Xpress 1:5000 Catalog#: R910-25, Invitrogen, 
USA 
Mouse-anti-β-actin  1:20000 Cat# 691001, MP Biomedicals, 
LLC 
Goat-Anti-Mouse IgG 
1:10000 for β-actin 
antibody 
1:5000 for Xpress 
antibody 
Cat# 119380, Jackson 
ImmunoResearch, USA 
Goat Anti-Rabbit IgG 1:10000 
Cat# 120745, Jackson 
ImmunoResearch, USA 
Goat Anti-Rat IgG 1:10000 Cat# 112-005-003 
Rabbit-anti-SUOM-1  1:125 (for 
immunoprecipitation) 




2.5. Data analysis and statistics 
Densitometric analysis of immunoblots was implemented with ImageLab 3.0 
software (BioRad, Hercules, CA). The SUMOylated 5-HT1A-R proteins 
levels were normalized to β-actin which is measured on a SDS-PAGE gel 
performed with membrane fraction used as the input for the 
immunoprecipitation. All data were analyzed by one-way analysis of variance 
(ANOVA) using the GraphPad Prism (version 6.02) followed Dunnett’s 
multiple comparisons test and the criterion of significance was set at p<0.05. 
Quantitative data are presented as the mean±SEM.  
 
2.6. Prediction of SUMOylation sites 
Previous studies indicated that most of SUMOylation sites follow a consensus 
motif of ΨKXE (ψ, a hydrophobic amino acid; X, any amino acid residue). It 
is possible to predict the SUMOylation sites in silico in order to narrow down 
the number of candidate sites and generate helpful information for further 
exploration. Here we used SUMOplot and PCI-SUMO programs to predict 
possible SUMOylation sites on the rat 5-HT1A-R. The sequence of rat 
5-HT1A-R was obtained from The National Center for Biotechnology 
Information (NCBI). Data are shown in Table 3. Lysine 302 has the highest 
score which suggests that it has the highest chance to be the SUMOylation 
site. 




Window of Residues Score 
 
232 FRIRKTVRKVEKKGAGT 0.1458 
235 TVKKVEKTGADTRH 0.33 
302 EVHRVGNSKEHLPLPSE 0.5633 
324 YAPACLERKNERNAEAK 0.2620 
332 KNERNAEAKRKMALARE 0.2643 
Table 3. Possible SUMOylated lysine residues and the sequence at which they 
















Chapter Ⅲ. Results 
3.1. Identification of Sentrin specific proteases of 5-HT1A-Rs. 
To investigate which SENP proteins are involved in the de-SUMOylation of 
5-HT1A-Rs, SENP proteins were transfected into N2a cells. I used several SENPs 
plasmids, FLAG-SENP1, FLAG-SENP2, MYC-SENP3, MYC-SENP5, RGS-SENP3, 
RGS-SENP5, and FLAG-SENP6. Cell membrane fractions were collected and the 
expression levels of each transfected SENPs were examined by immunoblotting with 
anti-FLAG, anti-MYC and anti-His antibodies. In the cell membrane fraction, 
transfected SENP1 was detected at 75kDa, transfected SENP2 was detected at 55kDa 
and transfected SENP6 was detected at 150kDa, all of which are the appropriate size 
(Figure 1A). Among the three SENPs, the SENP1 construct expressed most 
abundantly. The expression levels of SENP2 and SENP6 are very similar, and express 
at a lower level (Figure 1A). In the cell cytosol fraction, transfected SENP1, 2 and 6 
were detected at appropriate size as well however, the expression of SENP1 and 
SENP6 were quite abundant, SENP2 remained at a low expression level (Figure 1B). 
Several anti-MYC antibodies and anti-His antibodies were used to try to detect the 
transfected proteins, however none of them detected transfected proteins or positive 
controls. These results verify transfection and the expression of only FLAG-SENP1, 
FLAG-SENP2 and FLAG-SENP6 in N2a cells.  
 
To determine the effects of SENPs on SUMOylation of 5-HT1A-Rs, the cell 
membrane fraction was collected and immunoprecipitated with a SUMO-1 antibody 
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followed by immunoblotting with a 5-HT1A-R antibody. A 55kDa band in the 
membrane fraction was detected (Figure 1C) which is consistent with our previous 
findings that 5-HT1A-R can be SUMOylated by SUMO-1 protein in rat brain [24]. 
Based on our ability to confirm the over-expression of FLAG-SENP1, FLAG-SENP2 
and FLAG-SENP6, I used one-way ANOVA to compare the effects of these SENPs to 
the non-transfected control group. Statistical analysis shows that there is a significant 
difference in SUMO-1-5-HT1A-R levels among non-transfected, SENP1, 2 and 6 
transfected groups (n=5, One-way ANOVA, F (3, 15) = 4.15, p=0.025) (Figure 1D), 
but the Dunnett’s multiple comparisons test shows no significant difference between 
the non-transfected group compared to each SENP transfected group.  
 
Na+, K+ ATPase is a plasma membrane marker and was selected to verify separation 
of membrane and cytosolic fractions (Figure 1E). The results show that there was 
abundant Na+, K+ ATPase in the membrane fraction while there was no Na+, K+ 
ATPase detected in the cytosolic fraction, indicating successful separation of 
membrane and cytosol fraction. 
 
3.2. Overexpression of rat 5-HT1A-Rs in N2a cells. 
To identify the SUMOylation sites on 5-HT1A-Rs, we first determined whether the 
N2a cells can express transfected 5-HT1A-Rs and determined the optimal amount of 
5-HT1A-Rs constructs for overexpression. A rat 5-HT1A-R sequence was inserted 
into the pcDNA4HisMaxC plasmid. N2a cells were transfected with different 
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amounts of pcDNA4HisMaxC-5-HT1A-Rs plasmids. Immunoblotting with an Xpress 
antibody was used to identify the overexpressed 5-HT1A-Rs in both cytosol and 
membrane fraction. Our results show that the expression levels of transfected 
5-HT1A-Rs increased with the increasing amounts of 5-HT1A-Rs plasmids and 14ug 
of pcDNA4HisMaxC-5-HT1A-Rs plasmids resulted in an optimal expression level 
(Figure 2A).  
 
Next, to examine the SUMOylated 5-HT1A-Rs, different amounts of membrane 
proteins were collected and immunoprecipitated with a mouse SUMO-1 antibody 
followed by immunoblotting with mouse Xpress antibody. N2a cell membrane 
preparations containing 250, 350, 450, 550, 650 and 750ug were used for 
immunoprecipitation assays followed by immunoblotting with Xpress antibody. As 
Fig. 2B shows, we observed bands around 48kDa, 55kDa and above 70kDa (Figure 
2B). Unfortunately, mouse IgG heavy chain was detected at 55kDa which is the 
expected position of SUMO-1-5-HT1A-Rs, because the same species of antibody was 
used for immunoprecipitation and detection on the immunoblot. The SUMOylated 
5-HT1A-R levels detected were increased and correlated to the protein concentration 
in the range between 250 and 750 mg of protein. Based on this study, we used 450 mg 
of protein in subsequent experiments (Figure 2B). 
 
To prevent detection of IgG heavy chain, we chose a polyclonal rabbit SUMO-1 
antibody (donated by Dr. Yoshiaki Azuma) [75] to pull down the SUMOylated 
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proteins. The mouse Xpress antibody detected protein bands at ~48kDa and above 
~70kDa (Figure 2C). Bands at 48kDa and above 70kDa are not the predicted 
molecular size for SUMO 1- 5-HT1A-R complex as previously detected in different 
regions of rat brain tissue. In order to determine if the protein bands detected by 
Xpress antibody are SUMOylated 5-HT1A-Rs, we removed NEM (which inhibits 
deSUMOylation) from the buffers. When NEM was not used to harvest N2a cells and 
conduct immunoprecipitation experiments, the intensity of SUMOylated 5-HT1A-Rs 
was dramatically decreased, thus confirming that the band around 48 kDa and bands 
above 70kDa represents the SUMOylated 5-HT1A-Rs (Figure 2C).  
 
3.3. Identification of SUMOylation sites on 5-HT1A-Rs. 
SUMO proteins associate with target proteins at lysine residues. Thus, to identify the 
SUMOylation sites on 5-HT1A-Rs, possible SUMOylation sites: K302, K332, K324, 
K232 and K235 were mutated into nonSUMOylatable arginine residues. Each 
5-HT1A-R mutant was transfected into N2a cells. Membrane fractions were collected 
after 48 hours and immunoprecipitated with a rabbit SUMO-1 antibody followed by 
immunoblotting with a mouse Xpress antibody. Bands at 48kDa and above 70kDa 
were detected. As shown in Figure 3A, we quantified the 48kDa band and the 75kDa 
bands. Statistical analysis shows that there is no significant difference between 
mutants and wild-type 5-HT1A-R for either the 48kDa band (n=3, One-way ANOVA, 
F (6, 17) = 0.9182, p=0.5059) (Figure 3A) or the 75kDa band (n=3, One-way ANOVA, 
F (6, 14) = 0.1483, p=0.9864) (Figure 3A).    
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Next, we compared SUMOylation of endogenous 5-HT1A-Rs and SUMOylation of 
transfected 5-HT1A-Rs. The same PVDF membrane was incubated with a rabbit 
5-HT1A-R antibody to look at the SUMOylation of endogenous 5-HT1A-Rs. The 
endogenous SUMO-1-5HT1A-Rs were detected at 55kDa (Figure 3B). Next, we 
merged Figure 3A and Figure 3B together to compare the SUMOylation of 
endogenous 5-HT1A-Rs and transfected 5-HT1A-Rs. As shown in Figure 3C, the 
band of SUMOylated endogenous 5-HT1A-R is at 55kDa while the bands of 
SUMOylated transfected 5-HT1A-R is at 48KD, and above ~70kDa, suggesting that 
the transfected receptors that are SUMOylated are a different size than the 






















Figure 1. Identification of SENPs proteins in N2a cells. N2a cells were transfected 
with FLAG-SENP1, FLAG-SENP2, MYC-SENP3, MYC-SENP5, RGS-SENP3, 
RGS-SENP5, and FLAG-SENP6 plasmid constructs. The SUMO-1-5-HT1A-Rs were 
immunoprecipitated with a mouse SUMO-1 antibody followed by immunoblotting 
with a rabbit 5-HT1A-Rs antibody. (A). The expression of transfected SENPs in 
membrane fraction. (B). The expression of transfected SENPs in cytosol fraction. (C). 
The effect of SENPs proteins on SUMOylation of 5-HT1A-Rs (blots from all five 
independently repeated experiments are shown). (D). Quantification of 
SUMO-1-5-HT1A-Rs. Data are presented as mean±SEM (n=5). One-way ANOVA 
shows there is a significant difference among groups (F (3, 15) = 4.15, p=0.0251) but 
Dunnett’s multiple comparison test post-hoc test shows there is no significant 
difference comparing NT group to each SENPs group. (E). The separation of 
membrane fractions was verified by immunoblotting using Na+/K+ ATPase as plasma 
membrane marker. MT: Mock transfection. IgG: immunoprecipitation with the same 










Figure 2. Overexpression of rat 5-HT1A-Rs in N2a cells. (A). The N2a cells were 
transfected with different amount of pcDNA4HisMaxC-5-HT1A-R plasmids. 
Membrane fractions were isolated 48 hours after transfection and immunoblotted with 
a mouse Xpress antibody. Several bands were detected. A band near 42kDa might 
indicate the unmodified transfected 5-HT1A-Rs; a band around 50kDa might 
represent SUMO-1-5-HT1A-Rs; several bands above 50kDa might indicate other post 
translational modifications of transfected 5-HT1A-Rs. N2a cells can express 
pcDNA4HisMaxC-5-HT1A-R construct and 14ug of plasmids results in optimal 
expression levels. (B). 450ug of protein is an optimal amount for immunoprecipitation. 
250-750ug protein of cell membrane preparation was immunoprecipitated with a 
mouse SUMO-1 antibody and immunoblotted with a mouse Xpress antibody. (C). 
Protein bands at 48kDa, 70kDa~250kDa indicate the SUMOylation of transfected 
5-HT1A-Rs. Membrane fractions were isolated in the absence or presence of NEM. 
The bands at 48kDa and 70kDa~250kDa significantly decreased in the absence of 
NEM. A band at the top of the blot does not decreased in the absence of NEM 

















Figure 3. Identification of SUMOylation sites on 5-HT1A-Rs. Six 5-HT1A-R 
mutants were constructed and transfected into N2a cells, including K332R; K302R; 
K332,302R; K324R; K232,235R; K232,235,324R. (A). Membrane fraction was 
collected, immunoprecipitated with a rabbit SUMO-1 antibody and examined on 
immunoblots with a mouse Xpress antibody. The experiment was repeat five times 
(all blots from five repeats are shown). Quantification of 48kDa band and 75kDa band 
from 3 separate experiments shows that there is no significant difference between 
transfection groups for the 48kDa band (n=3, one-way ANOVA, F (6, 17) = 0.9182, 
p=0.5059). Quantification of 75kDa bands shows no significant difference between 
groups due to transfection of the mutant or wild-type 5-HT1A-R (n=3, one-way 
ANOVA, F (6, 14) = 0.1483, p=0.9864). (B). The immunoblot shown in the upper 
right corner was next incubated with a 5-HT1A-R antibody to look at the endogenous 
SUMOylation of 5-HT1A-Rs. A band at 55kDa was detected, which indicates the 
expression of SUMO-1-5-HT1A-Rs in the presence of NEM. SUMO-1-5HT1A-Rs 
were not detected in the absence of NEM which further verifies the band at 55kDa 
represents the SUMOylation of 5-HT1A-Rs. (C). Figure 3A and Figure 3B were 
merged. The 48kDa band does not overlap with 55kDa band, demonstrating that these 







Chapter Ⅳ. Discussion 
In this study, we focused on the deSUMOylation of 5-HT1A-Rs and the 
SUMOylation sites on 5-HT1A-Rs. Our studies have demonstrated that 1). 
Transfected SENP1, 2 and 6 can be expressed in the membrane fraction of N2a cells; 
2). Transfection of SENP1, 2 and 6 had a significant effect on de-SUMOylation of 
5-HT1A-Rs. 3); N2a cells express 5-HT1A-Rs and transfected rat 5-HT1A-Rs can be 
SUMOylated. 4); Transfection of 5-HT1A-R mutant has no significant effect on 
SUMOylation of 5-HT1A-Rs after statistical analysis of protein bands at 48kDa and 
75kDa; 5). SUMOylation of transfected rat 5-HT1A-Rs has different molecular mass 
bands compared to SUMOylation of endogenous 5-HT1A-Rs in N2a cells. 
 
There are 7 SENPs (SENP1, SENP2, SENP3, SENP5, SENP6, SENP7, and SENP8) 
in mammals. All these SENPs are involved in the regulation of SUMOylation except 
SENP8. Previous studies on SENPs demonstrated the distribution of SENPs in 
nucleus and cytosol, however, the SUMO machinery can also translocate to different 
regions of neurons during development [76, 77]. SUMO-1-5-HT1A-Rs are located at 
ER and Golgi, and in the detergent-resistant membrane (DRM) where the active 
5-HT1A-Rs are located. A previous study in which PIAS proteins were transfected 
into N2a cells confirmed the distribution of PIAS protein in the membrane. Here, I 
verified the expression of SENP1, 2 and 6 in membrane fraction of N2a cells and 
found that SENP1 was expressed more abundantly (Figure 1A) in the membrane 
fraction. However, in my experiment, I used sodium cholate to extract the 
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hydrophobic proteins located in the plasma membrane including DRM as well as 
Golgi and ER. To determine if SENP1 expressed more abundantly than other SENPs 
in the cell membrane, more evidence is required. For example, we can further isolate 
cell membrane by ultracentrifugation.  
 
In the experiment to identify the effect of SENPs on deSUMOylation of 5-HT1A-Rs, 
I also transfected MYC-SENP3, MYC-SENP5, RGS-SENP3, and RGS-SENP5 
constructs into N2a cells, but I was not able to detect the expression of these proteins. 
The MYC-SENP3, MYC-SENP5, RGS-SENP3 and RGS-SENP5 constructs were 
sequenced by ACGT, Inc. in order to rule out the possibility about incorrect sequence. 
Different MYC antibodies and RGS antibodies were used in the immunoblot but none 
of them can detected the expression of transfected proteins including the positive 
control. Since I could not verify the expression of these constructs, the effects of these 
SENPs on SUMOylation of 5-HT1A-Rs are unreliable. To solve this problem, we 
could try different antibodies for the MYC tagged and RGS tagged proteins or to 
choose SENPs specific antibodies to verify the expression of SENP proteins. 
 
Transfection of SENP2 seemed to decrease the SUMOylation of 5-HT1A-Rs (Figure 
1B), and one-way ANOVA showed there is a significant difference of SUMOylation 
of 5-HT1A-Rs after transfection with SENP1, 2 and 6. However the post-hoc test 
showed there was no significant difference when each transfected SENPs group was 
compared to the non-transfected control group. There are two possible explanations. 
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First, the variability of the data might contribute to the lack of statistical significance. 
Since SENP1, SENP2 and DESI-1 are the only three SUMO proteases that have a 
preference for SUMO-1 and 5-HT1A-Rs can be SUMOylated by SUMO-1, SENP1, 
SENP2, and DESI-1 are possibly involved in the deSUMOylation of 5-HT1A-Rs [50]. 
Moreover, there are no reports about the isopeptidase effects of DESI-1, suggesting 
that DESI-1 might not be involved in the cleavage of SUMO protein from its substrate 
[50]. Thus, SENP1 and SENP2 are more likely to play a role in the deSUMOylation 
of 5-HT1A-Rs, especially SENP2 according to the present study (Figure 1B). Another 
possible explanation is that deSUMOylation of 5-HT1A-Rs is processed by an 
undiscovered SUMO protease belonging to deSUMOylating isopeptidases. To further 
identify the SUMO proteases involved in the deSUMOylation of 5-HT1A-Rs, a 
fluorescence resonance energy transfer (FRET) assay can be performed [39]. FRET is 
a process by which the excited state energy of a fluorescent donor molecule is 
transferred to an acceptor molecule [39]. Efficient energy transfer requires very close 
proximity, and can therefore be used as a read-out for covalent protein interactions 
such as SUMOylation [39]. Moreover, a SUMO-CHOP-Reporter assay platform 
would be able to test the SUMO proteases activity to further study the mechanism of 
SUMOylation of 5-HT1A-Rs [39]. The SUMO-CHOP-Reporter assay platform was 
developed by Progenra, Inc. A reporter construct was created by fusing His6-tagged 
small ubiquitin-like modifier (SUMO) to the amino terminus of the reporter enzyme 
phospholipase A2 (PLA2) [39]. Following cleavage by a SENP, free PLA2 is able to 
hydrolyze its substrate, resulting in the release of a fluorescent product which is 
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readily quantifiable using a fluorimeter or a fluorescence plate reader  [39].  
 
Here, I expressed rat 5-HT1A-Rs in N2a cells and verified that rat 5-HT1A-Rs can be 
SUMOylated in N2a cells. In the initial experiment, I immunoblotted the membrane 
fraction with the same rabbit 5-HT1A-R antibody as I used in the SENPs experiment. 
However, there was no change in the level of 5-HT1A-Rs after transfection of rat 
5-HT1A-Rs (data not shown). The lack of expression of 5-HT1A-Rs might be due to 
the rabbit 5-HT1A-R antibody only recognizing endogenous 5-HT1A-Rs. So, we 
immunoblotted membrane fraction with a mouse Xpress antibody to detect Xpress 
tagged 5-HT1A-Rs in N2a cells (Figure 2A). A concentration-response assay showed 
that 14ug of plasmids transfection can express transfected 5-HT1A-Rs. To only look 
at SUMOylation of transfected 5-HT1A-Rs, I next immunoprecipitated membrane 
fractions with a mouse SUMO-1 antibody and immunoblotted with a mouse Xpress 
antibody. Unfortunately, mouse IgG heavy chain was detected at 55kDa which is the 
expect position of SUMO-1-5-HT1A-Rs. To prevent detection of IgG heavy and light 
chain, we chose another rabbit SUMO-1 antibody from Dr. Yoshiaki Azuma. The 
mouse Xpress antibody detected protein bands at ~48kDa and above ~70kDa. The 
bands were further verified in the absence of SUMO protease inhibitor NEM (Figure 
2C), suggesting SUMOylation of transfected 5-HT1A-Rs. To further confirm the 
SUMOylation of transfected 5-HT1A-Rs, N2a cells can be treated with SUMOylation 




Our lab previously reported several SUMOylated protein bands which were detected 
by a 5-HT1A-R antibody at ~75kDa, ~55kDa. The 55kDa band was consistently 
present but the 75kDa was not. The protein band at 55kDa was shown to be a 
SUMO-1 modified 5-HT1A-Rs, but the identity of the protein band at 75kDa remains 
unclear [24]. However, here we observed protein bands at ~48kDa and 
70kDa~250kDa but not 55kDa. Possible explanations include that 5-HT1A-Rs might 
be SUMOylated at multiple lysine sites, a cross-talk between SUMOylation and other 
post-translational modifications or the formation of polySUMO chains. The formation 
of polySUMO chains would significantly increase the molecular weight of 
SUMO-conjugation, which is consistent to the high molecular weight of bands. The 
editing of polySUMO chains by SENPs generate variable length SUMO chains, 
reflected on the SDS-PAGE as multimeric cleavage intermediates. The protein band at 
~48kDa might indicate one SUMO protein added to 5-HT1A-Rs as an intermediate 
since the predicted molecular weight of 5-HT1A-R is ~42kDa and a single SUMO-1 
protein is around 8~10kDa. Thus, the previously reported 55kDa protein band might 
result from two SUMO proteins bound to 5-HT1A-Rs. To further verify the formation 
of polySUMO chains, a SUMO-2/3 antibody could be used for immunoblotting, since 
polySUMO chains are formed by SUMO-2/3. Another alternative explanation is the 
crosstalk of other post-translational modifications on SUMO-1-5-HT1A-Rs. Studies 
have shown post-translational modifications involved in 5-HT1A-Rs include 
palmitoylation, glycosylation and phosphorylation. Glycosylation usually results in an 
additional high molecular weight polysaccharide to the protein and thus causes a high 
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molecular mass complex. Thus, the crosstalk between glycosylation and 
SUMOylation might contribute to the 70kDa~250kDa bands. Palmitoylation can add 
a single palmitoyl modification or be dually modified with one or more palmitoyl 
groups to cysteine and less frequently to serine and threonine residues of proteins. It is 
reported that palmitoylation of 5-HT1A-Rs occurs at Cys 417 and Cys 420 and the 
molecular weight of palmitoylated 5-HT1A-Rs is around 46kDa [21], it is possible 
that two palmitoyl groups are added to SUMO-1-5-HT1A-Rs and results in a 
molecular weight at ~55kDa. However, phosphorylation only provides an additional 
80Da phosphate group to the protein which does not seems to change the molecular 
weight of the protein by much. So, it is likely that the protein band at 55kDa is caused 
by the cross-talk between SUMOylation and palmitoylation, and two palmitoyl 
groups might added to the SUMO-1-5-HT1A-Rs. 
 
I speculate that the 55kDa band might be caused by two SUMO protein SUMOylation 
or two palmitoyl groups added to SUMO-1-5-HT1A-Rs and the 48kDa band from 
transfected 5-HT1A-Rs might be only one SUMO-1 protein SUMOylation. One 
possible reason that may have happened is that transfected 5-HT1A-R does not 
process through ER and Golgi and might not be palmitoylated, thus exists as a 48kda 
band instead of the 55kDa band. In my experiment, I used a lipofectamine 3000 
transfection method. This method can deliver foreign DNA plasmids into nucleus, but 
foreign DNA will not integrate with the host genome. In this way, it is possible that 
the expressed proteins do not process through ER and Golgi. In addition, the 
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70kDa~250kDa bands are more likely caused by SUMOylation at multiple sites than 
the glycosylation, because most of the glycosylation also occurs in ER and Golgi [78]. 
There is another possibility that those modified proteins aggregated together and 
formed high molecular complex. Thus, without processing through ER and Golgi 
network, the transfected 5-HT1A-Rs are unable to process post translational 
modifications like endogenous 5-HT1A-Rs and thus, causes different molecular 
weight bands. A transfection approach such as lentivirus might help solve this 
problem. Lentivirus are RNA viruses that carry a gene for a reverse transcriptase that 
transcribes the viral genetic material into a double stranded DNA intermediate [79]. 
This DNA intermediate is then incorporated into the host DNA allowing the host cell 
machinery to produce the desired protein [79]. Additionally, because the viral genome 
is stably integrated into the host DNA, any modification that has been made will be 
passed to all daughter cells that are derived from the transfected cell [79]. In this way, 
the transfected 5-HT1A-Rs can process post translational modifications and enter 
proper signaling pathways similar to the endogenous 5-HT1A-Rs.  
 
After transfection of rat 5-HT1A-R mutants into N2a cells, there is no significant 
difference in SUMOylation of 5-HT1A-Rs, which means the mutations failed to 
prevent 5-HT1A-Rs from SUMOylation. As I discussed above, the rat 5-HT1A-R 
might not be expressed properly. Another possible scenario is that other lysine 
residues got SUMOylated instead of 6 candidate lysine residues. A proteomic mass 
spectrometry approach would be able to tell us all the SUMOylation sites on 
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5-HT1A-Rs, however this approach requires a large amount of protein. 
 
In conclusion, my experiments found that N2a cells can express transfected 
5-HT1A-Rs, and that transfected SENP1, 2 and 6 are expressed in the membrane 
fraction of N2a cells. I also found that transfection of SENP1, 2, and 6 causes a 
significant difference among groups but additional works is needed to improve the 
observed variability and to allow for a more definitive conclusion with respect to 
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